Medtronic’s ITB Therapy shows benefits in stroke treatment study

Medtronic has announced the findings of a new study showing the benefits its Intrathecal Baclofen (ITB)Therapy can provide in the treatment of stroke patients.

Data from the SISTERS trial have demonstrated the superiority of ITB Therapy with Lioresal intrathecal injections, delivered via the SynchroMed II Infusion System compared, to conventional medical management among adults with severe post-stroke spasticity (PSS).

Results of the study showed that ITB Therapy delivered significant improvements in reducing muscle tone in the affected lower and upper extremities over a six-month period, while safety performance was generally consistent with the known profile.

PSS impacts up to 43 percent of patients in the first year after their stroke, and leads to the development of excessive muscle tone that can cause pain and stiffness, deformity and a reduced range of movement.

Charlie Covert, vice-president and general manager for targeted drug delivery at Medtronic, said: "We're committed to raising awareness of ITB Therapy as an effective treatment for severe PSS, and to ensure it is available to the patients who need it most."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.